Takeda to acquire TiGenix, IBD candidate

Takeda recently announced its intention to acquire TiGenix for more than 520 million euros, which will expand its late stage gastroenterology pipeline and strengthen its presence in the U.S. market, according to a press release.

The acquisition includes a stem cell therapeutic candidate under development by TiGenix for the treatment of fistulizing Crohn’s disease.

“As a leader in gastroenterology, Takeda recognizes the complex physical, emotional and social barriers that people living with fistulizing Crohn’s disease experience,” Andrew Plump, MD, Takeda’s chief medical and scientific officer, said in the press release “Limited treatment options exist today, and I believe we can be most effective in serving this population by working in collaboration with partners whose unique skill sets allow us to more effectively explore innovative approaches, including stem cell therapies.”

Takeda and TiGenix partnered in July 2016 to develop Cx601 (darvadstrocel), an investigational allogenic stem cell therapy for complex perianal fistulas in Crohn’s disease. In December, it received a positive opinion recommending marketing authorization from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), and from the Committee for Advanced Therapies (CAT).

Twenty-four-week data, published in The Lancet, showed Cx601 was superior vs. placebo for achieving combined remission, and that treatment-related adverse events and discontinuations due to adverse events were comparable between groups. The compound maintained long-term remission, according to follow-up data. A global, phase 3 trial for U.S. registration has begun for Cx601.

Takeda will purchase all outstanding shares of TiGenix ordinary shares, American Depository Shares, warrants and convertible bonds for 1.78 euros per share through a recommended potential voluntary public takeover bid, according to the press release. – by Alex Young

Disclosures: Plump is employed by Takeda.